Concerns about radiation are believed to be a major reason so few women pursue a career in interventional cardiology. Are they right to be worried? SCAI hopes its new analysis can shed some light on this topic. 

When heart patients require aortic valve replacement, would they be a better fit for TAVR or SAVR? Such decisions are not made lightly, clinicians emphasized in a new joint statement.

SCAI President Dawn Abbott, MD, MSCAI, aims to turn attention toward the long-term sustainability of the interventional cardiology field.

Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.

Two separate studies explored the value of treating heart patients with tirzepatide. 

Researchers explored data from more than 8,000 patients treated over a three-year period. 

SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, made a major impact on the group—and cardiology as a whole—over the last 12 months. 

Several U.S. medical societies have collaborated on a new report advocating for better safety standards in cardiac catheterization labs. As one cardiologist described it, clinicians have shifted from "accepting risk" to "expecting better."